- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04951245
Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy (UltraCars)
January 13, 2022 updated by: Kun Wang, Guangdong Provincial People's Hospital
Ultrasound-assisted Carbon Nanoparticle Suspensions Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy in Patients With Early Breast Cancer (UltraCars): a Prospective, Randomized Controlled Phase 3 Trial
The investigators suggested ultrasound-assisted Carbon nanoparticle suspensions (CNSs) mapping had great clinical value in clinical application and might serve as a useful alternative to the dual-tracer-guided SLNB.
The investigators designed this prospective, randomized controlled phase 3 trial, to compare the feasibility and diagnostic performance of ultrasound-assisted carbon nanoparticle suspensions mapping versus dual-tracer-guided sentinel lymph node biopsy in patients with early breast cancer.
Study Overview
Status
Completed
Conditions
Detailed Description
The study was a single-center, open-label, randomized controlled, non-inferiority, phase 3 trial.
Eligible participants were 18 year's of age or older and had histologically confirmed primary invasive breast cancer, or ductal carcinoma in situ scheduled for mastectomy, without clinical or radiological nodal involvement (cN0) or with clinical positive lymph nodes (cN1) that were downstaged to cN0 following neoadjuvant chemotherapy (NCT); and had an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Participants were randomly assigned (1:1) using a permuted block randomization scheme to receive either ultrasound-assisted CNSs (UC group) or CNSs plus ICG dual-tracer-guided (GC group) SLN mapping.
Study Type
Interventional
Enrollment (Actual)
330
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Guangzhou, China
- Guangdong General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion criteria:
- The participants must be female and 18 years of age or older.
- Resectable invasive adenocarcinoma of the breast, confirmed histologically.
- Ductal carcinoma in situ confirmed histologically.
- The participants must be a preoperative clinical Tis, T1, T2, T3 as well as clinical M0 breast cancer.
- Without clinical or radiological nodal involvement (cN0): No positive ipsilateral axillary lymph nodes; No prior removal of ipsilateral axillary lymph nodes; No suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless proven nonmalignant by biopsy.
- With clinical positive lymph nodes (cN1) (including any abnormal or enlarged clinically palpable lymph nodes or core biopsy/surgical biopsy/FNA evidence of malignant cell within any lymph nodes) that was downstaged to cN0 following neoadjuvant therapy.
- The participants must have an ECOG performance status of Grade 0-1.
- The participants must provide written informed consent before participating in the study.
Exclusion criteria:
- The breast has ulceration, erythema, infiltration of the skin or underlying chest wall (complete fixation), peau d'orange, or skin edema of any magnitude. Tethering or dimpling of the skin or nipple inversion allowed.
- The participants has a known hypersensitivity to tracers planned for use during SLNB.
- Other prior breast malignancy except lobular carcinoma in situ.
- The participants has had prior breast implants.
- The participants has had prior breast reduction surgery.
- The participants has had other prior surgery in the upper, outer quadrant, areola, or axilla to the indicated breast.
- The participants has a positive pregnancy test or is lactating.
- The participants has participated in another investigational drug study during the 30 days prior to signing informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: UC group
Ultrasound-assisted CNSs guided SLN mapping
|
1ml of CNSs was subcutaneously injected into the areolar area in the upper outer quadrant of the breast.
The injection site was massaged for 15 minutes to promote drainage of the tracer to the axilla.
During the intraoperative ultrasound-assisted procedure, an ultrasound diagnostic system was used.
Before the incision, ultrasound-guided exploration of SLNs was performed by placing the probe on the lateral border of the breast and sliding cranially along the lateral border of the pectoralis major muscle .
A sterile skin marker was then used to mark the optimal site of incision over the targeted lymph nodes, and the distance from the skin to the nodes was measured by ultrasound and recorded in millimeters.
Blunt dissection was carried out to identify the CNSs-stained nodes around the marked region.
Ultrasonography probe was placed repeatedly in or around the wound at different angles for adequate visualization if SLNs could not be localized with further dissection.
|
ACTIVE_COMPARATOR: GC group
CNSs plus ICG dual-tracer-guided SLN mapping
|
The preparation of CNSs mapping was identical to that of the UC group.
1ml of diluted ICG was subsequently injected into the areolar area in the upper outer quadrant of the breast.
A NIR camera was used to visualize the subcutaneous lymph vessels and localized the SLNs.
All fluorescent or black-stained lymph nodes along with any palpable suspicious nodes were removed.
The remaining surgical field was reexamined to ensure complete resection of fluorescent lymph nodes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The identification rate of SLNs
Time Frame: within 14 days of SLNB
|
Defined as the number of patients who at least one SLN were detected divided by the total number of patients included.
|
within 14 days of SLNB
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The mean number of SLNs collected
Time Frame: within 14 days of SLNB
|
Defined as the number of tracer-stained or palpable SLNs divided by the number of patients whose SLNs were identified.
|
within 14 days of SLNB
|
Operative time
Time Frame: within 14 days of SLNB
|
Defined as the time from skin incision to resection of the SLNs specimens in patients whose at least one SLN were detected.
|
within 14 days of SLNB
|
Intraoperative or postoperative complications
Time Frame: within 30 days of SLNB
|
An adverse event is any untoward, undesired, and/or unplanned clinical event in the form of signs, symptoms, disease, or laboratory testing, or physiological observations occurring in a human participating in a clinical study with a study drug, regardless of causal relationship.
|
within 30 days of SLNB
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification rate of SLNs in post-NCT patients
Time Frame: within 14 days of SLNB
|
Defined as the number of patients who at least one SLN were detected divided by the total number of patients included in NCT subgroup.
|
within 14 days of SLNB
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Kun Wang, MD, Guangdong Provincial People's Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 1, 2019
Primary Completion (ACTUAL)
April 30, 2021
Study Completion (ACTUAL)
June 1, 2021
Study Registration Dates
First Submitted
September 21, 2019
First Submitted That Met QC Criteria
June 26, 2021
First Posted (ACTUAL)
July 6, 2021
Study Record Updates
Last Update Posted (ACTUAL)
January 28, 2022
Last Update Submitted That Met QC Criteria
January 13, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20190511
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on UC group: ultrasound-assisted CNSs guided
-
Abant Izzet Baysal UniversityRecruiting
-
University of AlbertaCompleted
-
Asan Medical CenterRecruitingFemoropopliteal DiseaseKorea, Republic of
-
Seoul National University HospitalCompletedLabor AnalgesiaKorea, Republic of
-
National Cancer Institute, EgyptCompletedBreast Neoplasms | AnalgesiaEgypt
-
Uludag UniversityNot yet recruiting
-
Affiliated Hospital of Nantong UniversityRecruitingQuality of Recovery | Nerve BlockChina
-
University of Sao Paulo General HospitalCompletedPostoperative Pain | Rotator Cuff InjuriesBrazil
-
Kahramanmaras Sutcu Imam UniversityUnknownForearm Injuries | Hand Injuries
-
University of ChileCompletedPostoperative Complications | Postoperative Pain | Motor Activity | Weakness, MuscleChile